[ad_1]
Johnson & Johnson remains “very confident” in its COVID-19 vaccine and hopeful for a quick resolution from regulators over its status, a top executive said Tuesday.
“We remain very confident and very hopeful that the benefit-risk profile will play out,” J&J Chief Financial Officer Joseph Wolk told CNBC.
The comments came ahead of a decision expected later Tuesday from Europe’s drug regulator on the safety of the single-shot innoculation.
US pandemic advisor Anthony Fauci said the United States is likely to announce its decision by Friday.
Health authorities in the United States on April 14 recommended a pause on the vaccine following six instances of severe blood clots out of nearly seven million Americans who received the vaccine.
The company hopes “very shortly … perhaps as early as the end of this week, to have some resolution with how we are going to proceed,” Wolk said.
Asked if the US decision to suspend the program hindered public confidence in vaccines, Wolk said “I would hope that at the end of the week, the population in general will feel more confident in taking the vaccine.”
The comments came as J&J released first-quarter results.
An earnings press release did not elaborate on vaccine approval issues, but said the vaccine generated $100 million in revenues in the United States during the period. J&J is selling the vaccine at cost.
J&J has also encountered production problems at a Baltimore, Maryland factory managed by Emergent BioSolutions.
The Food and Drug Administration has suspended production in the plant pending a review of the facility.
Wolk said J&J expects to be “in a position to meet our contract commitments, not just here in the US but across the globe” following the FDA review.
Follow the latest news on the coronavirus (COVID-19) outbreak
© 2021 AFP
Citation:
J&J ‘very confident’ in vaccine, eyes quick resolution (2021, April 20)
retrieved 20 April 2021
from https://medicalxpress.com/news/2021-04-jj-confident-vaccine-eyes-quick.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
[ad_2]
Source link
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022
